{"id":2576,"date":"2021-05-04T18:12:40","date_gmt":"2021-05-04T12:42:40","guid":{"rendered":"https:\/\/schooltimesindia.com\/?p=2576"},"modified":"2021-05-04T18:12:40","modified_gmt":"2021-05-04T12:42:40","slug":"ministry-of-ayush-responds-to-faqs-about-ayush-64","status":"publish","type":"post","link":"https:\/\/schooltimesindia.com\/archives\/2576","title":{"rendered":"Ministry of Ayush responds to FAQs about \u201cAyush-64\u201d"},"content":{"rendered":"
New Delhi :\u00a0 Described by experts as a ray of hope in the time of the pandemic, the polyherbal drug AYUSH- 64 which was originally developed in 1980 for treatment of malaria, has now been repurposed for Covid 19. The Central Council for Research in Ayurvedic Sciences (CCRAS), a research institution under the Ministry of Ayush devoted to Ayurveda, recently concluded extensive and robust clinical trials of the drug in collaboration with the Council of Scientific and Industrial Research (CSIR) and many other research organizations and medical colleges across the country. The trials led by reputed scientists of the country showed AYUSH 64 has notable antiviral, immune-modulator and antipyretic properties. It is found to be useful in the treatment of asymptomatic, mild and moderate COVID-19 infection. Consequently, the drug is now repurposed for COVID-19.<\/p>\n
The announcement by the Ministry of the findings of the clinical trials in a press conference on 29th<\/sup>\u00a0April 2021 has led to considerable interest in AYUSH -64 among the public as well as medical practitioners. Responding to the numerous queries received in the matter, the Ministry has now released replies to the same in the Frequently Asked Questions (FAQs) format, and the same are reproduced below:<\/p>\n Ayush-64 is an Ayurvedic formulation, developed by the Central Council for Research in Ayurvedic Sciences (CCRAS), the apex body for research in Ayurveda under the Ministry of Ayush. Originally developed in 1980 for the management of Malaria, this drug has now been repurposed for Covid 19 as its ingredients showed notable antiviral, immune-modulator and antipyretic properties. The in-silico study done on Ayush 64 showed that 35 out of 36 of its Phyto-constituents have high binding affinity against COVID 19 virus. The formulation has also shown very promising results in Influenza like illnesses.\u00a0With scientific evidence generated from 06 clinical studies across India,\u00a0Ayush 64 has been identified as a potential adjunct to standard care in the management of asymptomatic, mild and moderate COVID 19 to improve the clinical recovery and quality of life.<\/p>\n <\/p>\n It can be taken by patients at any stage of the COVID-19 disease. However, its efficacy was scientifically studied in asymptomatic, mild and moderate disease without risk factors for poor outcome and those not requiring emergency interventions or hospitalization are eligible to take Ayush-64. Patients of mild to moderate COVID-19 cases showing initial symptoms like fever, malaise, body ache, nasal congestion, nasal discharge, headache, cough etc. and of asymptomatic cases of COVID-19 can start taking Ayush 64 within 7 days of diagnosis of the disease through RT-PCR for better outcome.<\/p>\n <\/p>\n Ayush-64 is found to significantly enhance the speed of clinical recovery in terms of disease symptoms and severity.\u00a0It also has significant beneficial effects on general health, fatigue, anxiety, stress, appetite, general wellbeing and sleep.<\/p>\n <\/p>\n Ayush-64 is a poly herbal formulation developed in compliance to all regulatory requirements as well as quality and pharmacopoeial standards by the Central Council for Research in Ayurvedic Sciences (CCRAS) the apex body for research in Ayurveda under the Ministry of Ayush. It has been scientifically established to be useful in the treatment of asymptomatic, mild and moderate COVID-19 infection as an adjunct to standard care through robust clinical trials conducted in the country.\u00a0The results of the clinical trials demonstrated that Ayush 64 as an adjunct to standard of care (SoC) showed clinically significant improvement and thus lesser period of hospitalization as compared to SoC alone.<\/p>\n <\/p>\n\n
\n
\n
\n